Relief Cardiovascular Completes First-in-Human Implant of Smart Cardiac Device, Pioneering a New Approach to Heart Failure Therapy
Relief Cardiovascular
Researcher on Novel Implantable Devices for Hemorrhagic Heart Failure
October 1, 2025, headquartered in Irvine, California, USARelief CardiovascularRecently announced the successful completion of itsTranscatheter Implanted Intelligent Cardiac DeviceThe first human use of Relief Cardiovascular. This groundbreaking attempt was completed at the Tbilisi Cardiovascular Center in Georgia, marking the company'sHemodynamic Monitoring and Treatment FunctionIntegrated within the same implant, marking a new era in heart failure treatment.
Relief Cardiovascular was founded in2022, headquartered in California, USA, is aEarly Stage of Series A's cardiovascular implant device company. The company has raised approximately$13.5 million, including the completion in early 2025.$12 Million Series A Financing, with an estimated valuation range of$48 million to $72 million. The team size is small (within 10 people), and the current focus of resources is onDevelopment and First Human Clinical Trial of Intelligent Cardiac Implant System, which is a typical early-stage deep-tech medical device startup.
Co-founder and CEO of the companyAlexander CooperHasBiomedical Engineering Background and MBA from UCLA Anderson School of Management, once inEdwards LifesciencesEngaged in R&D and clinical project management, with combined technical and commercial experience. Relief Cardiovascular was incubated by a medical incubator.inQB8 Medical TechnologiesIncubated and secured in Round A financingAdvent Life Sciences、Broadview Ventureswith the support of professional investment parties, its board of directors has also attracted senior figures from the cardiovascular and investment fields.
Product and Technical Features
The system of Relief Cardiovascular is implanted inInferior vena cava (vena cava)ofPressure-Guided Active Valve. It has the following core characteristics:
- Dual Function Fusion
It can not only monitor hemodynamic data in real time, but also dynamically reduce cardiac preload and enhance renal venous return as needed, thereby alleviating fluid retention and congestion in heart failure patients. - Individualized "Decongestion"
Through data-driven algorithms, the device can be adjusted on demand, directly acting on hemodynamics to achieve individualized decongestion therapy. - Cloud Connection
After implantation, the system automatically synchronizes with the cloud every night, allowing doctors to access patients' continuous monitoring data to support further treatment plans. - Implanted via catheter
Avoiding open-chest surgery, it has the advantages of minimal trauma and high repeatability.
The company said that this device represents aA New Paradigm of Treatment: UseData-Driven Therapeutic ImplantsTo directly manage the fluid status of heart failure patients.
Clinical Progress
First Human Implant byDr. Tamaz Shaburishvili, Dr. Levan Sulakvelidze, Dr. Gigi ShaburishviliCompleted at the Tbilisi Cardiovascular Center in Georgia, Professor of Cardiology at the University of Sheffield, UKAlex RothmanAs a member of the international expert team, provide support.
The first group of patients who received the treatment have been discharged smoothly and maintained daily data synchronization between the device and the cloud. The clinical team reported that immediate and adjustable hemodynamic effects were observed after implantation, offering new therapeutic possibilities for heart failure patients.
According to the company's disclosure, this trial belongs toFeasibility Study (Feasibility Study), mainly evaluating the safety and preliminary efficacy of the system.
"Future of the Heart" Observation
The attempt by Relief Cardiovascular showsThe function of cardiovascular implants is moving from "passive support" towards "active treatment."：
Recent Article Recommendations
GCC2025
